Retatrutide and Research Peptides for Weight Loss: What's Real vs Hype

Retatrutide is an investigational Eli Lilly drug that acts on three hormone receptors (GIP, GLP-1, and glucagon), and it is not FDA-approved as of October 5, 2026. The trial results are real: in a published 80-week phase 3 trial, average body weight changed by up to -25.0% versus -3.9% on placebo. The "research peptide" vials sold online are a different thing entirely.

A plain note first: this is general information, not medical advice. It contains no dosing, sourcing, or how-to information, on purpose. Talk to your prescriber about any weight-loss medication, approved or not.

What retatrutide actually is

Retatrutide (Lilly's code name LY3437943) is described in its trial publications as an agonist of three receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. That is why headlines call it a "triple agonist." For comparison, the FDA describes Zepbound (tirzepatide) as activating two of those receptors, GLP-1 and GIP, and Wegovy (semaglutide) as a GLP-1 receptor agonist.

Lilly is the company running the trials, and the published papers list Lilly as the funder. That matters when you read the results: the studies are randomized, double-blind, and peer reviewed, but they are sponsor-funded, and the long-term picture beyond the trial windows is not yet published.

The single most important fact for anyone seeing retatrutide on social media: it is still an investigational medicine. A Lilly-registered expanded access listing on ClinicalTrials.gov, last updated August 2026, describes it as "an investigational GLP-1/GIP/glucagon triple receptor agonist being studied for chronic weight management." In its August 5, 2026 earnings release, Lilly said it plans "to submit a Biologics License Application to the U.S. FDA in the first quarter of 2027." A drug that has not yet been submitted for approval cannot be FDA-approved, and the FDA's own GLP-1 statement (content current as of October 1, 2026) says retatrutide is not a component of any FDA-approved drug.

The real clinical evidence, trial by trial

Here is what the published trials report, labeled by phase and duration. All figures are averages for groups of people in controlled trials under medical supervision. I have left out the dose amounts deliberately; the point here is what the evidence shows, not how anyone would take it.

Trial	Phase, duration	Who was studied	Average body weight change	Placebo
Jastreboff et al., NEJM 2023	Phase 2, 48 weeks	338 adults with obesity, or overweight plus a weight-related condition	-8.7% to -24.2% across dose groups	-2.1%
TRIUMPH-1, NEJM 2026	Phase 3, 80 weeks	2,339 adults with obesity, without diabetes	-17.6%, -23.7%, and -25.0% across three dose groups	-3.9%
TRIUMPH-2, Lancet 2026	Phase 3, 80 weeks	1,152 adults with obesity or overweight and type 2 diabetes	-11.9%, -16.8%, and -18.8% across three dose groups	-5.1%

Phase 2 (2023)

The phase 2 trial, published in the New England Journal of Medicine by Jastreboff and colleagues, randomized 338 adults to weekly injections of retatrutide at several dose levels or placebo for 48 weeks. At 48 weeks, the least-squares mean change in body weight ranged from -8.7% in the lowest dose group to -24.2% in the highest, versus -2.1% with placebo. In the highest dose group, 100% of participants lost 5% or more of their body weight and 83% lost 15% or more, compared with 27% and 2% on placebo.

The authors reported that the most common adverse events were gastrointestinal, "dose-related, were mostly mild to moderate in severity," and partially mitigated by a lower starting dose. They also reported "dose-dependent increases in heart rate" that peaked at 24 weeks and then declined.

Phase 3: TRIUMPH-1 (2026)

TRIUMPH-1 was published in the NEJM on September 29, 2026. It enrolled 2,339 adults with obesity and without diabetes and ran for 80 weeks. Mean percent change in body weight was -17.6%, -23.7%, and -25.0% in the three retatrutide groups versus -3.9% with placebo. The trial also measured knee osteoarthritis pain in a subgroup of 574 participants and sleep apnea events in 243 participants with obstructive sleep apnea, and reported improvements on both versus placebo. The most common adverse events were gastrointestinal.

Phase 3: TRIUMPH-2 (2026)

TRIUMPH-2, published in The Lancet the same day, studied 1,152 adults with a BMI of 27 or higher and type 2 diabetes for 80 weeks. Mean body weight change was -11.9%, -16.8%, and -18.8% in the three retatrutide groups versus -5.1% on placebo. Nausea was reported in 14% to 28% of the retatrutide groups versus 8% on placebo, and diarrhea in 27% to 34% versus 13%. Stopping treatment because of adverse events or death occurred in 12% and 8% of the two higher dose groups, compared with 4% in the lowest dose group and 5% on placebo. Seven participants died across all groups; the investigators deemed all deaths unrelated to the study drug.

What the evidence does not tell you

These are the honest limits. The published trials run 48 to 80 weeks, so they cannot speak to what happens over many years. A cardiovascular and kidney outcomes trial (TRIUMPH-Outcomes) is registered on ClinicalTrials.gov, but I found no published results for it. And every number above came from pharmaceutical-grade drug given inside a trial with medical monitoring, which is the central point of the next section.

Why "research peptide" retatrutide is not the same thing

Search retatrutide and you will find websites selling vials labeled "research use only." The FDA has addressed this directly. Its statement on unapproved GLP-1 drugs used for weight loss says the agency has cautioned against products "falsely labeled 'for research purposes' or 'not for human consumption'" containing "semaglutide, tirzepatide, retatrutide, survodutide or mazdutide," which were "sold directly to consumers for human use with dosing instructions."

The same FDA page states plainly: "Retatrutide and cagrilintide cannot be used in compounding under federal law," and "these are not components of FDA-approved drugs and have not been found safe and effective for any condition." The trials used Lilly's investigational product under a protocol, with doctors watching. A vial from an unregulated seller has had no FDA review of what is in it, how much, or how it was made and stored. The FDA's warning about counterfeit products applies here too: counterfeit drugs "claim to be authentic, but could contain the wrong ingredients."

Other trending weight-loss peptides

I am only including peptides where an FDA page or a published trial says something specific. Anything else on peptide social media is outside what this post can verify.

Peptide	What a primary source says	Source
Retatrutide	Investigational; cannot be compounded; not a component of any FDA-approved drug	FDA GLP-1 statement; ClinicalTrials.gov
Cagrilintide	"Cannot be used in compounding under federal law"; not a component of FDA-approved drugs	FDA GLP-1 statement
Survodutide, mazdutide	Named by the FDA among ingredients in products falsely labeled "for research purposes"	FDA GLP-1 statement
Semaglutide, tirzepatide	Active ingredients in FDA-approved drugs, but also named in falsely labeled "research" products	FDA GLP-1 statement; FDA approvals

BPC-157 gets its own breakdown in our BPC-157 research guide, including which evidence comes from animals versus humans.

The FDA also notes that compounded versions of approved drugs are a separate issue from research peptides: "Compounded drugs are not FDA approved," and "the agency does not review compounded drugs for safety, effectiveness or quality." The agency reports receiving 990 adverse event reports associated with compounded semaglutide and more than 730 for compounded tirzepatide, as of May 31, 2026.

What is actually approved today

If you want a medication for weight management today, the approved route is through a prescriber. Two of the best-known options:

Drug	Active ingredient	How the FDA describes it	FDA approval for weight management
Wegovy	Semaglutide	GLP-1 receptor agonist	June 2021, adults with obesity, or overweight plus at least one weight-related condition
Zepbound	Tirzepatide	Activates GLP-1 and GIP receptors	November 8, 2023, adults with a BMI of 30 or higher, or 27 or higher plus a weight-related condition

Both were approved by the FDA for use "in addition to a reduced calorie diet and increased physical activity." That phrase is easy to skip, but it means food still matters on every plan. If you are on one of these, how many calories to eat on Ozempic covers intake on a smaller appetite, and protein on a GLP-1 covers the nutrient that gets hardest to hit when you are eating less.

Where food tracking fits, whatever your plan

No medication on this page replaces eating well, and none of the trials above were about any app. What tracking can do is make your eating visible, which is useful whether you are on an approved prescription, in a trial, or on no medication at all.

I built Nouri because the first tracker I used was too slow to keep up with, and the photo trackers after it gave numbers that came in low when I checked them. That problem gets sharper on a small appetite: meals turn into a few bites of yogurt, half a sandwich, a protein shake, and none of them feel worth a five-minute database search. In Nouri, each of those takes a sentence. You can type what you ate like a note, say it out loud, snap a photo (Nouri turns it into a sentence first so you can correct it), or say "Hey Siri, track food in Nouri" from the lock screen. Calories and macros come back instantly with per-item reasoning, and you can add context like "half portion" and recalculate.

Protein is the number most worth watching when you eat less. Nouri's Prioritize Protein setting raises your protein target from 1.0 g per pound of body weight to 1.2 g, keeps fat at 30% of calories, and lets carbs absorb the difference. Your prescriber or dietitian should set your personal target; the setting just makes whichever target you use visible every day.

The weekly view is where small days add up. Nouri Reports, part of Nouri Premium, arrive after your first 3 logged days, then every Sunday evening when you log 4 or more days: average calories and macros against your targets, days on target judged by your goal, protein equivalents, and one clear focus for next week. Most calorie apps give you numbers. Nouri gives you answers. Nouri is a food log, not a treatment, and it is not designed for any medication. It runs on iPhone (iOS only), and you can start from the App Store.

Common mistakes when reading peptide hype

Treating trial results as product results. The -25.0% figure came from an 80-week phase 3 trial of Lilly's investigational drug under medical supervision. It says nothing about what is inside an unregulated vial.

Confusing "phase 3 complete" with "approved." Lilly's own August 2026 release says the FDA application is planned for early 2027. Approval, if it comes, is a separate FDA decision.

Assuming "research use only" is a legal loophole. The FDA calls these labels false when products are sold to consumers for human use.

Ignoring food because the drug "does the work." Both approved drugs above are approved alongside a reduced-calorie diet. Smaller meals make protein and fiber more important, not less.

Reading averages as promises. Trial results are group averages, and not every participant reaches the average.

FAQ

Is retatrutide FDA approved?

No. As of October 5, 2026, retatrutide is an investigational drug. Lilly's August 2026 earnings release says it plans to submit a Biologics License Application to the FDA in the first quarter of 2027, and the FDA's GLP-1 statement says retatrutide is not a component of any FDA-approved drug.

How much weight did people lose on retatrutide in trials?

In the phase 3 TRIUMPH-1 trial, adults with obesity and without diabetes had mean body weight changes of -17.6% to -25.0% across three dose groups over 80 weeks, versus -3.9% on placebo. In the 48-week phase 2 trial, the highest dose group averaged -24.2% versus -2.1% on placebo. These are trial averages, not individual predictions.

What is a triple agonist?

It means one drug acts on three hormone receptors. Retatrutide's trial papers describe it as an agonist of GIP, GLP-1, and glucagon receptors. Zepbound acts on two (GLP-1 and GIP), and Wegovy acts on one (GLP-1).

Is research peptide retatrutide the same as the drug in the trials?

There is no way to verify that it is. The FDA says products "falsely labeled 'for research purposes'" containing retatrutide have been sold to consumers for human use, and that retatrutide has "not been found safe and effective for any condition." Unregulated products get no FDA review of identity, purity, or quality.

Is it legal to compound retatrutide?

According to the FDA, no: "Retatrutide and cagrilintide cannot be used in compounding under federal law."

What are the side effects of retatrutide?

In the published trials, the most common adverse events were gastrointestinal. In TRIUMPH-2, nausea occurred in 14% to 28% of retatrutide groups versus 8% on placebo, and the phase 2 trial reported dose-dependent increases in heart rate that peaked at 24 weeks. Long-term safety data beyond the trial windows have not been published.

When will retatrutide be available?

Lilly has said it plans to submit to the FDA in the first quarter of 2027, and FDA review comes after that. Lilly also lists a pre-approval expanded access program on ClinicalTrials.gov for a narrow group of adults with severe obesity, provided on a single-patient basis.

What weight-loss drugs are FDA approved right now?

Wegovy (semaglutide) and Zepbound (tirzepatide) are two FDA-approved options for chronic weight management in adults who meet BMI criteria. Both are approved for use alongside a reduced-calorie diet and increased physical activity, and both require a prescription.

Do you still need to track food on a GLP-1 medication?

The FDA approvals pair these drugs with a reduced-calorie diet, so what you eat still matters. Eating less can make protein harder to hit; see protein on a GLP-1. Ask your prescriber what targets fit you.

What is the easiest way to track food when your appetite is small?

Use a method that makes tiny meals as fast to log as big ones. In Nouri, "half a turkey sandwich and a few bites of yogurt" is one sentence, typed, spoken, snapped, or said to Siri, and the Sunday report rolls those small days into your weekly protein and calorie averages.

Retatrutide's published trial data are genuinely strong, and it is still not an approved drug, so anything sold online under its name today is a different story. If you are on an approved plan, log your meals in Nouri and pair it with our guides on calories on Ozempic and hitting protein on a GLP-1.

Sources

• Jastreboff AM et al., "Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial," New England Journal of Medicine, 2023, pubmed.ncbi.nlm.nih.gov/37366315 (checked October 5, 2026)
• Jastreboff AM et al., "Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity" (TRIUMPH-1), New England Journal of Medicine, published online September 29, 2026, pubmed.ncbi.nlm.nih.gov/42814954 (checked October 5, 2026)
• Bellido V et al., "Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2)," The Lancet, published online September 29, 2026, pubmed.ncbi.nlm.nih.gov/42810372 (checked October 5, 2026)
• FDA, "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss," content current as of October 1, 2026, fda.gov (checked October 5, 2026)
• Eli Lilly Q2 2026 earnings release (Form 8-K exhibit), August 5, 2026, sec.gov (checked October 5, 2026)
• ClinicalTrials.gov: Pre-approval Expanded Access of Retatrutide, NCT07629401; TRIUMPH-1, NCT05929066; TRIUMPH-Outcomes, NCT06383390 (checked October 5, 2026)
• FDA, "FDA Approves New Medication for Chronic Weight Management" (Zepbound), November 8, 2023, fda.gov (checked October 5, 2026)
• FDA Office of Women's Health, June 2021 e-Update (Wegovy approval), fda.gov (checked October 5, 2026)